{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,6]],"date-time":"2025-02-06T16:10:03Z","timestamp":1738858203973,"version":"3.37.0"},"reference-count":29,"publisher":"Oxford University Press (OUP)","issue":"565","license":[{"start":{"date-parts":[[1972,11,1]],"date-time":"1972-11-01T00:00:00Z","timestamp":89424000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[1972,11,1]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>Various pharmacological approaches to potentiate the therapeutic actions of levodopa and reduce side-effects are reviewed.<\/jats:p><jats:p>Of currently available drugs, anticholinergic agents and amantadine have been studied extensively. Inhibition of extracerebral decarboxylase appears to be the most promising new area of investigation, though experience is at present limited.<\/jats:p><jats:p>Other methods discussed include inhibition of enzymes catechol-O-methyl transferase, monoamine oxidase and dopamine beta hydroxylase. Conflicting evidence on 3-O-methyldopa is discussed.<\/jats:p>","DOI":"10.1136\/pgmj.48.565.653","type":"journal-article","created":{"date-parts":[[2008,12,29]],"date-time":"2008-12-29T20:27:15Z","timestamp":1230582435000},"page":"653-656","source":"Crossref","is-referenced-by-count":2,"title":["Augmenting the action of levodopa"],"prefix":"10.1093","volume":"48","author":[{"given":"S K","family":"Rao","sequence":"first","affiliation":[{"name":"Department of Medicine, The Royal Postgraduate Medical School and Hammersmith Hospital , London, W. 12"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S D","family":"Vakil","sequence":"additional","affiliation":[{"name":"Department of Medicine, The Royal Postgraduate Medical School and Hammersmith Hospital , London, W. 12"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D B","family":"Calne","sequence":"additional","affiliation":[{"name":"Department of Medicine, The Royal Postgraduate Medical School and Hammersmith Hospital , London, W. 12"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A","family":"Hilson","sequence":"additional","affiliation":[{"name":"Department of Neurology, The Royal Free Hospital , London, W.C.1"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[1972,11,1]]},"reference":[{"key":"ref_1","article-title":"Abstracts of papers. Seventh International Congress of Neurology, Excerpta Medica Foundation","author":"BARBEAU, A.","year":"1961","unstructured":"BARBEAU, A. (1961) Abstracts of papers. Seventh International Congress of Neurology, Excerpta Medica Foundation, Amsterdam."},{"key":"ref_2","first-page":"802","article-title":"The pathogenesis of Parkinson's disease: A new hypothesis","volume":"87","author":"BARBEAU, A.","year":"1962","unstructured":"BARBEAU, A. (1962) The pathogenesis of Parkinson's disease: A new hypothesis. Canadian Medical Association Journal, 87, 802.","journal-title":"Canadian Medical Association Journal"},{"key":"ref_3","first-page":"791","article-title":"L-dopa therapy in Parkinson's disease","volume":"101","author":"BARBEAU, A.","year":"1969","unstructured":"BARBEAU, A. (1969) L-dopa therapy in Parkinson's disease. Canadian Medical Association Journal, 101, 791.","journal-title":"Canadian Medical Association Journal"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1038\/215852b0","article-title":"Increase of cerebral catecholamines caused by 3, 4-dihydroxyphenylalanine after inhibition of peripheral decarboxylase","volume":"215","author":"BARTHOLINI, G.; BURKARD, W.P.; PLETSCHER, A.; BATES, H.M.","year":"1967","unstructured":"BARTHOLINI, G., BURKARD, W.P., PLETSCHER, A. & BATES, H.M. (1967) Increase of cerebral catecholamines caused by 3, 4-dihydroxyphenylalanine after inhibition of peripheral decarboxylase. Nature, 215, 852.","journal-title":"Nature"},{"key":"ref_5","first-page":"192","article-title":"Third Symposium on Parkinson's Disease","author":"BARTHOLINI, G.; TISSOT, R.; PLETSCHER, A.","year":"1969","unstructured":"BARTHOLINI, G., TISSOT, R. & PLETSCHER, A. (1969) Third Symposium on Parkinson's Disease (Ed. by F. J. Gillingham and I. M. L. Donaldson), p. 192. Livingstone, Edinburgh."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1136\/bmj.2.5708.540","article-title":"Adjuvants to L-dopa for Parkinsonism","volume":"3","author":"BRAHAM, J.","year":"1970","unstructured":"BRAHAM, J. (1970) Adjuvants to L-dopa for Parkinsonism. British Medical Journal, 3, 540.","journal-title":"British Medical Journal"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1136\/bmj.3.5777.729","article-title":"Idiopathic Parkinsonism treated with an extracerebral decarboxylase inhibitor in combination with levodopa","volume":"3","author":"CALNE, D.B.; REID, J.L.; VAKIL, S.D.; RAO, S.; PETRIE, A.; PALLIS, C.A.; GAWLER, J.; THOMAS, P.K.; HILSON, A.","year":"1971","unstructured":"CALNE, D.B., REID, J.L., VAKIL, S.D., RAO, S., PETRIE, A., PALLIS, C.A., GAWLER, J., THOMAS, P.K. & HILSON, A. (1971a) Idiopathic Parkinsonism treated with an extracerebral decarboxylase inhibitor in combination with levodopa. British Medical Journal, 3, 729.","journal-title":"British Medical Journal"},{"key":"ref_8","first-page":"162","article-title":"Extracerebral decarboxylase inhibition in Parkinsonism. Proceedings of Asian and Oceanic Congress of Neurology, Bombay","volume":"44","author":"CALNE, D.B.; REID, J.L.; VAKIL, S.D.; RAO, S.; PALLIS, C.A.; THOMAS, P.K.; HILSON, A.","year":"1971","unstructured":"CALNE, D.B., REID, J.L., VAKIL, S.D., RAO, S., PALLIS, C.A., THOMAS, P.K. & HILSON, A. (1971b) Extracerebral decarboxylase inhibition in Parkinsonism. Proceedings of Asian and Oceanic Congress of Neurology, Bombay (in press). CALNE, D.B., PETRIE, A., RAO, S., REID, J.L., & VAKIL, S.D. (1972) Action of L-alpha methyldopahydrazine on the blood pressure of patients receiving levodopa. British Journal of Pharmacology, 44, 162.","journal-title":"British Journal of Pharmacology; Action of L-alpha methyldopahydrazine on the blood pressure of patients receiving levodopa"},{"year":"1969","author":"COTZIAS, G.C.; PAPAVASILIOU, P.S.; GELLENE, R.","key":"ref_9","unstructured":"COTZIAS, G.C., PAPAVASILIOU, P.S. & GELLENE, R. (1969)"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1056\/NEJM196902132800701","article-title":"Modification of Parkinsonism-chronic treatment with L-dopa","volume":"280","unstructured":"Modification of Parkinsonism-chronic treatment with L-dopa. New England Journal of Medicine, 280, 337.","journal-title":"New England Journal of Medicine"},{"key":"ref_11","first-page":"577","article-title":"Coupling of hypotensive and anti-Parkinson effects with two dopaminergic drugs","volume":"19","author":"DUBY, S.E.; DAHL, L.K.; COTZIAS, G.C.","year":"1971","unstructured":"DUBY, S.E., DAHL, L.K. & COTZIAS, G.C. (1971) Coupling of hypotensive and anti-Parkinson effects with two dopaminergic drugs. Clinical Research, 19, 577.","journal-title":"Clinical Research"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/0022-510X(71)90088-8","article-title":"Potentiation of the L-dopa effect in man by the use of catechol-O-methyltransferase inhibitors","volume":"14","author":"ERICSSON, A.L.","year":"1971","unstructured":"ERICSSON, A.L. (1971) Potentiation of the L-dopa effect in man by the use of catechol-O-methyltransferase inhibitors. Journal of the Neurological Sciences, 14, 193.","journal-title":"Journal of the Neurological Sciences"},{"key":"ref_13","article-title":"Combined treatment of Parkinsonism with L-dopa and amantadine","volume":"383","author":"GODWIN-AUSTEN, R.B.; FREARS, C.C.; BERGMANN, S.; PARKES, J.D.; KNILL-JONES, R.P.","year":"1970","unstructured":"GODWIN-AUSTEN, R.B., FREARS, C.C., BERGMANN, S., PARKES, J.D. & KNILL-JONES, R.P. (1970) Combined treatment of Parkinsonism with L-dopa and amantadine. Lancet, ii, 383.","journal-title":"Lancet"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/S0022-3565(25)27684-4","article-title":"The effect ofdisulfiram on catecholamine levels in the brain","volume":"157","author":"GOLDSTEIN, M.; NAKAJIMA, K.","year":"1967","unstructured":"GOLDSTEIN, M. & NAKAJIMA, K. (1967) The effect ofdisulfiram on catecholamine levels in the brain. Journal of Pharmacology and Experimental Therapeutics, 157, 96.","journal-title":"Journal of Pharmacology and Experimental Therapeutics"},{"key":"ref_15","first-page":"103","article-title":"Amantadine-dopamine interaction: possible mode of action in Parkinsonism","volume":"169","author":"GRELAK, R.P.; CLARK, R.; STUMP, J.M.; VERNIER, V.G.","year":"1970","unstructured":"GRELAK, R.P., CLARK, R., STUMP, J.M. & VERNIER, V.G. (1970) Amantadine-dopamine interaction: possible mode of action in Parkinsonism. Science, 169, 103.","journal-title":"Science"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1038\/231054a0","article-title":"Fusaric (5-butylpicolinic) acid, an inhibitor of dopamine beta hydroxylase, affects serotonin and noradrenaline","volume":"231","author":"HIDAKA, H.","year":"1971","unstructured":"HIDAKA, H. (1971) Fusaric (5-butylpicolinic) acid, an inhibitor of dopamine beta hydroxylase, affects serotonin and noradrenaline. Nature, 231, 54.","journal-title":"Nature"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/S0031-6997(25)07154-6","article-title":"Dopamine (3 hydroxytyramine) and brain function","volume":"18","author":"HORNYKIEWICZ, 0","year":"1966","unstructured":"HORNYKIEWICZ, 0. (1966) Dopamine (3 hydroxytyramine) and brain function. Pharmacological Reviews, 18, 925.","journal-title":"Pharmacological Reviews"},{"issue":"487","key":"ref_18","article-title":"Levodopa in Parkinsonism: the effects of withdrawal of anticholinergic drugs","volume":"2","author":"HUGHES, R.C.; POLGAR, J.G.; WEIGHTMAN, D.; WALTON, J.N.","year":"1971","unstructured":"HUGHES, R.C., POLGAR, J.G., WEIGHTMAN, D. & WALTON, J.N. (1971) Levodopa in Parkinsonism: the effects of withdrawal of anticholinergic drugs. British Medical Journal, 2 487.","journal-title":"British Medical Journal"},{"key":"ref_19","article-title":"Combined treatment of Parkinsonism with L-dopa and amantadine","volume":"566","author":"HUNTER, K.R.; STERN, G.M.; LAURENCE, D.R.; P, A.R.M.I.T.A.G.E.","year":"1970","unstructured":"HUNTER, K.R., STERN, G.M., LAURENCE, D.R., & ARMITAGE P. (1970a) Combined treatment of Parkinsonism with L-dopa and amantadine. Lancet, ii, 566.","journal-title":"Lancet"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1136\/bmj.3.5719.388","article-title":"Monoamine oxidase inhibitors and L-dopa","volume":"3","author":"HUNTER, K.R.; BOAKES, A.J.; LAURENCE, D.R.; STERN, G.M.","year":"1970","unstructured":"HUNTER, K.R., BOAKES, A.J., LAURENCE, D.R. & STERN, G.M. (1970b) Monoamine oxidase inhibitors and L-dopa. British Medical Journal, 3, 388.","journal-title":"British Medical Journal"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1001\/jama.1971.03190250055027","article-title":"Levodopa, involuntary movements and fusaric acid","volume":"218","author":"MENA, I.; COURT, J.; COTZIAS, C.","year":"1971","unstructured":"MENA, I., COURT, J. & COTZIAS, C. (1971) Levodopa, involuntary movements and fusaric acid. Journal of the American Medical Association, 218, 1829.","journal-title":"Journal of the American Medical Association"},{"key":"ref_22","first-page":"1130","article-title":"Amantadine dosage in treatment of Parkinson's disease","volume":"i,","author":"PARKES, J.D.; ZILKHA, K.J.; MARSDEN, P.; BAXTER, R.C.H.; KNILL-JONES, R.P.","year":"1970","unstructured":"PARKES, J.D., ZILKHA, K.J., MARSDEN, P., BAXTER, R.C.H. & KNILL-JONES, R.P. (1970) Amantadine dosage in treatment of Parkinson's disease. Lancet, i, 1130.","journal-title":"Lancet"},{"key":"ref_23","series-title":"Proceedings of Asian and Oceanic Congress of Neurology","article-title":"Hypotension induced by levodopa","author":"REID, J.L.; CALNE, D.B.; RAO, S.; GEORGE, C.F.; VAKIL, S.D.; PALLIS, C.A.","year":"1971","unstructured":"REID, J.L., CALNE, D.B., RAO, S., GEORGE, C.F., VAKIL, S.D. & PALLIS, C.A. (1971c) Hypotension induced by levodopa. Proceedings of Asian and Oceanic Congress of Neurology, Bombay (in press)."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1136\/bmj.4.5727.93","article-title":"L-dopa treatment failure: Explanation and correction","volume":"4","author":"RIVERA-CALIMLIM, L.; DUJOVNE, C.A.; MORGAN, J.P.; LASAGNA, L.; BIANCHINE, J.R.","year":"1970","unstructured":"RIVERA-CALIMLIM, L., DUJOVNE, C.A., MORGAN, J.P., LASAGNA, L. & BIANCHINE, J.R. (1970) L-dopa treatment failure: Explanation and correction. British Medical Journal, 4, 93.","journal-title":"British Medical Journal"},{"key":"ref_25","first-page":"301","article-title":"Interactions of L-dopa and amantadine in Parkinsonism","volume":"12","author":"SACKS, O.; SCHWARTZ, W.F.; MESSELOFF, C.R.","year":"1971","unstructured":"SACKS, O., SCHWARTZ, W.F. & MESSELOFF, C.R. (1971) Interactions of L-dopa and amantadine in Parkinsonism. Clinical Pharmacology and Therapeutics, 12, 301.","journal-title":"Clinical Pharmacology and Therapeutics"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1038\/229414a0","article-title":"Therapeutic implications in Parkinsonism of m-tyramine formation from L-dopa in man","volume":"229","author":"SANDLER, M.; GOODWIN, B.L.; RUTHVEN, C.R.J.; B, C.A.L.N.E.D.","year":"1971","unstructured":"SANDLER, M., GOODWIN, B.L., RUTHVEN, C.R.J., & CALNE D.B. (1971) Therapeutic implications in Parkinsonism of m-tyramine formation from L-dopa in man. Nature, 229, 414.","journal-title":"Nature"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1001\/jama.1969.03160070046011","article-title":"Amantadine in the treatment of Parkinson's disease","volume":"208","author":"SCHWAB, R.S.; ENGLAND, A.C.; POSKANZES, D.C.; YOUNG, R.R.","year":"1969","unstructured":"SCHWAB, R.S., ENGLAND, A.C., POSKANZES, D.C. & YOUNG, R.R. (1969) Amantadine in the treatment of Parkinson's disease. Journal of the American Medical Association, 208, 1168.","journal-title":"Journal of the American Medical Association"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/BF00404181","article-title":"Treatment of Parkinsonism with L-dopa in association with a dacarboxylase inhibitor. First objective results","volume":"2","author":"SIEGFRIED, J.; ZEIGLER, W.H.; REGLI, F.; FISCHER, C.; KAUFMANN, W.; PERRET, E.","year":"1969","unstructured":"SIEGFRIED, J., ZEIGLER, W.H., REGLI, F., FISCHER, C., KAUFMANN, W. & PERRET, E. (1969) Treatment of Parkinsonism with L-dopa in association with a dacarboxylase inhibitor. First objective results. Pharmacologia Clinica, 2, 23.","journal-title":"Pharmacologia Clinica"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1111\/j.2042-7158.1970.tb10592.x","article-title":"Potentiation by amantadine hydrochloride Of L-dopa-induced effects in mice","volume":"22","author":"SVENSSON, T.H.; STR6MBERG, U.","year":"1970","unstructured":"SVENSSON, T.H. & STR6MBERG, U. (1970) Potentiation by amantadine hydrochloride Of L-dopa-induced effects in mice. Journal of Pharmacy and Pharmacology, 22, 639.","journal-title":"Journal of Pharmacy and Pharmacology"}],"container-title":["Postgraduate Medical Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/pmj\/article-pdf\/48\/565\/653\/50253135\/postgradmedj-48-653.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/pmj\/article-pdf\/48\/565\/653\/50253135\/postgradmedj-48-653.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,6]],"date-time":"2025-02-06T15:35:30Z","timestamp":1738856130000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/pmj\/article\/48\/565\/653\/7064941"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1972,11,1]]},"references-count":29,"journal-issue":{"issue":"565","published-online":{"date-parts":[[1972,11,1]]},"published-print":{"date-parts":[[1972,11,1]]}},"URL":"https:\/\/doi.org\/10.1136\/pgmj.48.565.653","relation":{},"ISSN":["0032-5473","1469-0756"],"issn-type":[{"type":"print","value":"0032-5473"},{"type":"electronic","value":"1469-0756"}],"subject":[],"published-other":{"date-parts":[[1972,11]]},"published":{"date-parts":[[1972,11,1]]}}}